| Page 3 of 3 < |
Health Highlights: July 16, 2008
|
Discussion Policy
Comments that include profanity or personal attacks or other inappropriate comments or material will be removed from the site. Additionally, entries that are unsigned or contain "signatures" by someone other than the actual author will be removed. Finally, we will take steps to block users who violate any of our posting standards, terms of use or privacy policies or any other policies governing this site. Please review the full rules governing commentaries and discussions. You are fully responsible for the content that you post.
|
Recalled 'Lean Pockets' Sandwiches May Contain Plastic Pieces
Nestle is recalling 199,417 pounds of "Lean Pockets" frozen stuffed chicken sandwiches that may contain pieces of plastic, the U.S. Department of Agriculture said.The recall involves 9-ounce boxes of "Lean Pockets Spinach Artichoke Chicken - 2 sandwiches." Affected packages have a "best before" date of "Nov 2009," followed by a package code starting with "8144 544616." The establishment number "P7721A" is printed on the side of the package.The sandwiches were produced May 23 and distributed to retailers nationwide.
Two unspecified injuries have been reported to the company, the USDA's Food Safety and Inspection Service said on its Web site.
Consumers with questions should contact Nestle at 800-350-5016.
-----
Drug Thwarts Bone Loss in Prostate Cancer Patients: Study
Amgen's experimental bone-loss drug denosumab increased bone density and prevented fractures among clinical trial participants being treated for prostate cancer, theWall Street Journalreported, citing company research.
The injected drug was evaluated among 1,400 men who were being treated with prostate cancer therapy that blocks male hormones including testosterone, increasing their risk for weakened bones and fractures. Those who took denosumab fractured vertebrae at less than half the rate of those who took a placebo, the newspaper said.
The drug works by blocking certain immune system defenses, which could increase users' risk of infection. Serious infections were reported among 6 percent of denosumab users, versus 5 percent of those who took a placebo.
An estimated 186,000 U.S. men will be diagnosed with prostate cancer this year, the American Cancer Society predicts. And according to the National Cancer Institute, about half of all men with the disease are treated at some point with hormone therapy, the newspaper said.


